StockNews.com Begins Coverage on International Tower Hill Mines (NYSEAMERICAN:THM)
by Mitch Edgeman · The Markets DailyStockNews.com started coverage on shares of International Tower Hill Mines (NYSEAMERICAN:THM – Free Report) (TSE:ITH) in a research note published on Thursday morning. The firm issued a sell rating on the mining company’s stock.
International Tower Hill Mines Price Performance
THM opened at $0.42 on Thursday. The company has a market capitalization of $84.81 million, a price-to-earnings ratio of -21.24 and a beta of 1.18. International Tower Hill Mines has a 1-year low of $0.33 and a 1-year high of $0.80.
Hedge Funds Weigh In On International Tower Hill Mines
An institutional investor recently bought a new position in International Tower Hill Mines stock. Herr Investment Group LLC acquired a new stake in shares of International Tower Hill Mines Ltd. (NYSEAMERICAN:THM – Free Report) (TSE:ITH) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,052,246 shares of the mining company’s stock, valued at approximately $1,416,000. Herr Investment Group LLC owned approximately 1.03% of International Tower Hill Mines at the end of the most recent quarter. Institutional investors own 54.63% of the company’s stock.
About International Tower Hill Mines
International Tower Hill Mines Ltd. engages in the acquisition, exploration, and development of mineral properties. It holds rights to acquire interests in the Livengood gold project covering an area of approximately 19,546 hectares located to the northwest of Fairbanks, Alaska. The company was formerly known as Tower Hill Mines Ltd.
Recommended Stories
- Five stocks we like better than International Tower Hill Mines
- How to buy stock: A step-by-step guide for beginners
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Are Growth Stocks and Investing in Them
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Health Care Stocks Explained: Why You Might Want to Invest
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside